More for AtCor
Thursday, 24 July, 2008
AtCor Medical [ASX: ACG] has reached new supply agreements for its SphygmoCor blood-pressure measurement systems.
The contracts are worth at least a combined $1.66 million. AtCor has secured $2.8 million worth of contracts in the past 60 days.
SphygmoCor is a blood pressure monitoring system that identifies the effects of reflected blood pressure in the central aortic pressure wave.
The company has sold over 1,400 SphygmoCors to medical institutions and research institutions conducting clinical trials, as the device can be used to measure the effects of medication on central blood pressure.
Defective sperm doubles pre-eclampsia risk in IVF patients
A high proportion of the father's spermatozoa possessing DNA strand breaks is associated with...
Free meningococcal B vaccines coming to the NT
The Northern Territory Government has confirmed the rollout of a free meningococcal B vaccine...
Mouth bacteria linked to increased head and neck cancer risk
More than a dozen bacterial species that live in people's mouths have been linked to a...
